Back
The Barcelona Clínic Liver Cancer (BCLC) group, within the framework of the Clínic Barcelona Comprehensive Cancer Center —a center promoted by Clínic, IDIBAPS, and UB— has published the new version of the guidelines for managing hepatocellular carcinoma (HCC), the most frequent primary liver cancer.

The Barcelona Clínic Liver Cancer (BCLC) group, within the framework of the Clínic Barcelona Comprehensive Cancer Center —a center promoted by Clínic, IDIBAPS, and UB— has published the new version of the guidelines for managing hepatocellular carcinoma (HCC), the most frequent primary liver cancer.

The update incorporates the latest scientific advances and maintains its role as a global reference for clinical decision-making. It also introduces the CUSE concept (Complexity – Uncertainty – Subjectivity – Emotion), an innovative tool that supports clinical teams in making decisions tailored to each patient’s context.

The BCLC 2025 guidelines, published in the Journal of Hepatology, have been coordinated by the Liver Oncology Unit (BCLC) at Clínic-IDIBAPS, led by Dr. Maria Reig, who is also a researcher at the CIBER for Liver and Digestive Diseases (CIBEREHD). They have involved the participation of international specialists in hepatology, general and digestive surgery, pathology, nursing, radiology, medical and radiation oncology, and statistics. Additionally, Mr. Xavier Marcet and Dr. Katharine Damico contributed to the development of the CUSE concept, providing expertise in their respective fields.

---

Monday November 03, 2025